Prana settles clioquinol litigation

22 August 2004

Australia's Prana Biotechnology and the Massachusetts General Hospitalin the USA have agreed to settle all outstanding litigation with PN Gerolymatos of Greece regarding the exploitation rights to certain patents relating to pharmaceutical compositions and uses of clioquinol. As a result, Prana and the Greek firm have agreed to recognize the rights of each other to develop clioquinol in their respective territories, with the USA and Japan going to Prana and Europe and other markets for Gerolymatos.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight